Health

  • February 09, 2026

    9th Circ. Judge Casts Doubt On Feds' Grant Condition Stance

    A Ninth Circuit judge expressed skepticism Monday as the Trump administration argued it could legally impose new rules barring federal grant recipients from using the money for diversity programming, suggesting that the government had misread Title VI of the Civil Rights Act of 1964.

  • February 09, 2026

    Kurin Fights $1.6M IP Verdict As Rival Seeks More Damages

    Kurin has urged a Delaware federal judge to overturn Magnolia Medical's $1.6 million patent verdict or order a new trial, while Magnolia Medical has asked the court to bar Kurin from selling allegedly infringing "Jet" blood-culture collection products and award it supplemental damages on Kurin's sales, plus ongoing royalties and interest.

  • February 09, 2026

    Defendant Mix-Up Ends Biotech FCA Suit, For Now

    A New York federal court ruled that a relator's False Claims Act suit failed to link claims of improper COVID-19 billing and other alleged schemes to defraud Medicare to the biotech company it named as a defendant, dismissing the complaint with leave to amend.

  • February 09, 2026

    5th Circ. Tosses Challenge To La. 340B Discount Drug Rule

    A Fifth Circuit panel upheld on Monday a Louisiana law that allows the state to stop prescription drug manufacturers from blocking safety-net healthcare providers from contracting with outside pharmacies to dispense discounted medicines under the federal 340B Discount Drug program. 

  • February 09, 2026

    Anti-Abortion Groups Say Mich. Law Impedes 1st Amendment

    Two Michigan-based anti-abortion organizations are suing several officials, alleging recent amendments to Michigan's civil rights law will force them to hire employees and volunteers who do not share or may openly oppose their religious beliefs and stance on abortion.

  • February 09, 2026

    Insurer Fights To Keep Wrongful Death Coverage Suit Alive

    A Liberty Mutual unit should be able to proceed with its suit over coverage for a healthcare company facing eight wrongful death actions, the insurer told a Texas federal court, saying the present action is the only one in which the question of coverage is presently and properly joined.

  • February 09, 2026

    Wellstar Accused Of Causing Man's Death Via Colonoscopy

    Wellstar Health System and one of its Georgia locations have been hit with a federal lawsuit from a pair of siblings who allege that their father died after a doctor inflicted a "severe injury" to his colon and spleen during a routine colonoscopy.

  • February 09, 2026

    States Seek Quick Win On $100K H-1B Fee 'Power-Grab'

    A group of 20 states asked a Massachusetts federal judge for a win in their challenge to the Trump administration's policy imposing a $100,000 fee on certain H-1B visa petitions, arguing the measure unlawfully rewrites Congress' carefully calibrated immigration scheme and exceeds executive authority.

  • February 09, 2026

    Medical Equipment Co. Nets Tentative Deal In Overbilling Suit

    Medical supply giant AdaptHealth Corp. has tentatively settled an overbilling suit brought by a proposed class of patients who claim they were overcharged for home healthcare equipment, according to a North Carolina court order pausing upcoming deadlines in the case.

  • February 09, 2026

    Novo Nordisk Sues Hims & Hers Over Knockoff GLP-1

    Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.

  • February 09, 2026

    High Court Asked To Take Up Malpractice Case Against Akin

    A former Cornell University graduate student wants the U.S. Supreme Court to review the dismissal of his suit accusing Akin Gump Strauss Hauer & Feld LLP attorneys of manipulating patent litigation to steal his DNA sequencing intellectual property.

  • February 09, 2026

    Paul Weiss, Goodwin Steer Eli Lilly's $2.4B Orna Buy

    Pharmaceutical giant Eli Lilly & Co., advised by Paul Weiss Rifkind Wharton & Garrison LLP, on Monday announced that it has agreed to buy Goodwin Procter LLP-led biotechnology firm Orna Therapeutics Inc. in a deal where Orna shareholders could receive up to $2.4 billion in cash.

  • February 09, 2026

    Safanad Sells UK Care Home Biz To REIT For $1.6B

    Principal-led investment company Safanad announced Monday that it sold U.K. care-home provider HC-One to a healthcare real estate investment trust for over $1.6 billion.

  • February 06, 2026

    Ga. Panel Backs Sperm Bank Win In 'Wrongful Birth' Case

    A Georgia appeals court backed a win for sperm bank Xytex Corp. in consolidated litigation alleging the company sold sperm under false pretenses about the medical, psychological and social history of the donors.

  • February 06, 2026

    HHS Refers Hims & Hers To DOJ Amid Compound Drug Fight

    U.S. Department of Health and Human Services general counsel Mike Stuart announced Friday that his office referred Hims & Hers Health Inc. to the U.S. Department of Justice for investigation, a day after Novo Nordisk A/S threatened litigation over what it called the telehealth company's "knockoff" version of its popular weight loss drug Wegovy.

  • February 06, 2026

    'Very Bizarre': Trump's Funding Freeze Appeal Vexes DC Circ.

    D.C. Circuit judges struggled Friday with whether to unblock a federal funding freeze carrying multitrillion-dollar implications, as a Trump administration lawyer disclaimed interest in a vast spending halt but also dodged opportunities to rule it out unequivocally.

  • February 06, 2026

    11th Circ. OKs Immunity Denial In Fla. Excessive Force Case

    The Eleventh Circuit ruled Friday that two Florida police officers named in a civil lawsuit should not be granted qualified immunity for their conduct during a Baker Act arrest of a person they knew to be mentally unwell.

  • February 06, 2026

    NJ Judge Tosses Pacira Investor Suit Over Patent Loss

    A New Jersey federal judge on Friday threw out an investor lawsuit against Pacira BioSciences Inc. after a court invalidated a patent for its key pain management drug, ruling that the pharmaceutical company was not required to disclose litigation setbacks it encountered before the final ruling.

  • February 06, 2026

    Contractor Says VA's Uber Deal Is Taking Away Driving Biz

    The U.S. Department of Veterans Affairs violated the law when it awarded contracts to Uber and Onward Health to transport patients in San Francisco because the process was not transparent, the owner of a small transportation company alleged in a federal claims court suit.

  • February 06, 2026

    Colo. Nonprofit Drops Suit Over Medicaid Therapy Cuts

    A Colorado healthcare nonprofit Thursday voluntarily dismissed its complaint seeking to reverse an allegedly unlawful executive order signed by Gov. Jared Polis that cut state Medicaid spending to pediatric behavioral therapy and autism therapy services. 

  • February 06, 2026

    Arizona Abortion Restrictions Found Unconstitutional

    An Arizona state court permanently struck down a slew of restrictions on abortion care in the state, including an ultrasound mandate and a ban on the mailing of abortion pills, finding that the restrictions violate the right to abortion enshrined in the state's constitution.

  • February 06, 2026

    PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test

    The Patent Trial and Appeal Board has found that Geneoscopy had shown that all the claims it challenged in a patent on Exact Sciences' colon cancer test Cologuard are invalid as obvious, months after the PTAB invalidated claims in a similar patent.

  • February 06, 2026

    3rd Circ. Remands J&J Unit's Libel Suit Over Talc Study

    Johnson & Johnson's talc liability unit will get another chance to pursue libel claims against a scientist over an article she wrote linking talcum power to mesothelioma, after the Third Circuit agreed to send the case back to New Jersey federal court. 

  • February 06, 2026

    Ex-Yale New Haven Hospital Exec Drops Covenant Payment Suit

    A Connecticut federal judge has accepted a deal to dismiss a lawsuit claiming Yale New Haven Hospital withheld $994,000 in contractually required payments to its former chief operating officer, but said the parties can reopen the dispute if they need the court's intervention.

  • February 06, 2026

    Ex-President Accuses Physician AI Co. Of Fraud, Wage Theft

    A data science platform and its top brass persuaded its former chief strategy officer and president to invest $750,000 in the business, only then to not pay him wages, the former employee told a North Carolina federal court, claiming he's owed more than $430,000 in commission wages.

Expert Analysis

  • Series

    The Biz Court Digest: How It Works In Massachusetts

    Author Photo

    Since its founding in 2000, the Massachusetts Business Litigation Session's expertise, procedural flexibility and litigant-friendly case management practices have contributed to the development of a robust body of commercial jurisprudence, say James Donnelly at Mirick O’Connell, Felicia Ellsworth at WilmerHale and Lisa Wood at Foley Hoag.

  • How Healthcare Practices Can Prepare For ICE Visits

    Author Photo

    Healthcare providers that may face encounters with immigration enforcement should familiarize themselves with compliance obligations beyond ensuring employment authorization, and mitigate risk by establishing clear policies and specific procedures that safeguard patient rights and manage staff interactions with agents, say attorneys at Roetzel & Andress.

  • Adapting To Calif.'s Enhanced Regulation Of PE In Healthcare

    Author Photo

    New California legislation enhances oversight on the role of private equity groups and hedge funds in healthcare transactions, featuring both a highly targeted nature and vague language that will require organizations to carefully evaluate existing practices, says Andrew Demetriou at Husch Blackwell.

  • Why Appellees Should Write Their Answering Brief First

    Author Photo

    Though counterintuitive, appellees should consider writing their answering briefs before they’ve ever seen their opponent’s opening brief, as this practice confers numerous benefits related to argument structure, time pressures and workflow, says Joshua Sohn at the U.S. Department of Justice.

  • Navigating DEA Quotas: Key To Psychedelics Industry Growth

    Author Photo

    As new compounds like DOI enter the Schedule I landscape, manufacturers who anticipate U.S. Drug Enforcement Administration quota regulations, and build quota management into their broader strategy, will be best equipped to meet the growing demand, say Kimberly Chew at Husch Blackwell and Jaime Dwight at Promega.

  • Federal Acquisition Rules Get Measured Makeover

    Author Photo

    The Trump administration's promised overhaul of the Federal Acquisition Regulation is not a revolution in rules, but a meaningful recalibration of procurement practice that gives contracting officers more space to think, to tailor and to try, say attorneys at Mayer Brown.

  • Series

    Mindfulness Meditation Makes Me A Better Lawyer

    Author Photo

    Mindful meditation enables me to drop the ego, and in helping me to keep sight of what’s important, permits me to learn from the other side and become a reliable counselor, says Roy Wyman at Bass Berry.

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Calif. Justices Continued Anti-Arbitration Trend This Term

    Author Photo

    In the 2024-2025 term, the California Supreme Court justices continued to narrow arbitration's reach under state law, despite state courts' extreme caseload backlog and even as they embraced contractual autonomy in other contexts, says Josephine Petrick at The Norton Law Firm.

  • Steps For Healthcare Providers After Cigna ERISA Settlement

    Author Photo

    Following the Cigna class action's settlement, where Employee Retirement Income Security Act violations arose from Cigna's online provider directory advertising providers as in-network who were actually out-of-network, providers should routinely audit their contract status and directory listings, and proactively coordinate with plans and payor partners, say attorneys at ArentFox Schiff.

  • DOJ's UnitedHealth Settlement Highlights New Remedies Tack

    Author Photo

    The use of divestitures and Hart-Scott-Rodino Act compliance in the recent U.S. Department of Justice settlement with UnitedHealth Group and Amedisys underscores the DOJ Antitrust Division's willingness to utilize merger remedies under the second Trump administration, say attorneys at Buchanan Ingersoll.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.